Lancet Infectious Diseases

Article	Citations
A clinical case definition of post-COVID-19 condition by a Delphi consensus	1259
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial	1084
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study	1005
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	911
Clinical features and management of human monkeypox: a retrospective observational study in the UK	793
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study	752
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study	643
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance	601
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	598
COVID-19 and multisystem inflammatory syndrome in children and adolescents	580
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study	560
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study	547
Genomic evidence for reinfection with SARS-CoV-2: a case study	512
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult	472
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2	465
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study	446
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical	417
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries	352
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study	348
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression	345
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2	345
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study	338
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study	337
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis	331
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial	306

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison	298
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study	290
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study	268
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial	267
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data	263
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis	257
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study	253
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people	253
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised	244
Scaling up COVID-19 rapid antigen tests: promises and challenges	243
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England	237
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial	232
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT	231
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial	228
Willingness to vaccinate against COVID-19 in Australia	221
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont	221
The global incidence and diagnosis of fungal keratitis	220
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri	212
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study	211
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and	209
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study	203
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	200
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	199
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis	198
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5	195
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study	194
Intention to vaccinate against COVID-19 in Australia	192
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design	191
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study	185
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial	184
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis	177
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review	174
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav	173
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis	170
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study	169
What reinfections mean for COVID-19	168
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding	167
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard	164
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study	157
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity	157
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study	157
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study	155
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis	154
Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure	152
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective obse	151
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis	149
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies	148
Monoclonal antibody therapies against SARS-CoV-2	148
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US	147
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study	145

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial	144
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	143
Prevention of monkeypox with vaccines: a rapid review	143
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study	138
Monkeypox outbreaks outside endemic regions: scientific and social priorities	138
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England	138
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB	135
China's successful control of COVID-19	134
Concerns and motivations about COVID-19 vaccination	129
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study	129
Bell's palsy and SARS-CoV-2 vaccines	127
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms	127
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and An	127
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled	124
ChatGPT and antimicrobial advice: the end of the consulting infection doctor?	123
Hospitalisation among vaccine breakthrough COVID-19 infections	122
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial	118
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation	118
Tracking the 2022 monkeypox outbreak with epidemiological data in real-time	118
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions	117
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study	117
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study	116
Protective immunity after recovery from SARS-CoV-2 infection	115
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2	115
Global incidence and mortality of severe fungal disease	115
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe	115
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies	114
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis	114
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (CO	114
Genomic-informed pathogen surveillance in Africa: opportunities and challenges	114
Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study	114
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial	113
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study	113
RT-PCR for SARS-CoV-2: quantitative versus qualitative	111
Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study	108
The urgent need for metallo-β-lactamase inhibitors: an unattended global threat	108
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study	108
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial	107
Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study	107
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review	107
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2	106
100 years of Mycobacterium bovis bacille Calmette-Guérin	106
Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis	105
Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study	102
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant	102
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial	101
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant	100
Virological characteristics of the SARS-CoV-2 JN.1 variant	99
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant	99
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86	98
Hand hygiene in health care: 20 years of ongoing advances and perspectives	98
The importance of understanding the infectious microenvironment	96
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial	96
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	96
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM	95
Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019	95
Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort	95
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study	94
Viral loads in clinical samples of men with monkeypox virus infection: a French case series	94
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland	93
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study	92
The place for remdesivir in COVID-19 treatment	92
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis	92
The world's largest COVID-19 vaccination campaign	92
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial	91
Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis	91
Long COVID in the skin: a registry analysis of COVID-19 dermatological duration	90
Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study	89
Lung fibrosis: an undervalued finding in COVID-19 pathological series	88
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study	88
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study	86
Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study	85
Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study	84
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5	84
Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study	83
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial	82
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3	81
Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study	81
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation	81
Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant	80

First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020	79
Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis	79
The intersection of COVID-19 and mental health	78
Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective	78
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	77
The scientific and ethical feasibility of immunity passports	76
Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy s	76
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study	76
Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis	75
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial	74
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study	74
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21	73
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark	73
The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned	73
The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation	72
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controll	72
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases	70
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	70
Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain	69
Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, a	69
Antibiotic prescribing in general practice during COVID-19	68
COVID-19 vaccine equity and booster doses	68
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac	68
Quantifying the global number of tuberculosis survivors: a modelling study	68
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens	67
25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward	67
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	67
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study	67
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccinati	67
Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology a	66
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate	66
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial	66
Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019	66
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negati	65
CoronaVac induces lower neutralising activity against variants of concern than natural infection	64
Global increases in antibiotic consumption: a concerning trend for WHO targets	64
Persistence of IgG response to SARS-CoV-2	64
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak	64
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study	64
Long COVID: tackling a multifaceted condition requires a multidisciplinary approach	64
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies	63
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants	63
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study	63
Why we need a deeper understanding of the pathophysiology of long COVID	62
The first WHO global survey on infection prevention and control in health-care facilities	62
Prevention of host-to-host transmission by SARS-CoV-2 vaccines	60
Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis	60
Hospitalisation associated with SARS-CoV-2 delta variant in Denmark	60
Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study	60
Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection	60
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	59
India's COVID-19 vaccination drive: key challenges and resolutions	59
A case of SARS-CoV-2 reinfection in Ecuador	59
Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity	59
Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control	58
Associations between phone mobility data and COVID-19 cases	58
Increased risk of hospitalisation and death with the delta variant in the USA	58
New nomenclature for mpox (monkeypox) and monkeypox virus clades	58
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study	58
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudin	57
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 20	57
Effectiveness of BNT162b2 against COVID-19 in adolescents	56
Global COVID-19 vaccine inequity	56
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system	56
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial	56
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a random	55
Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study	55
CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants	55
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	55
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial	55
Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional survey	55
Evasion of neutralising antibodies by omicron sublineage BA.2.75	54
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial	54
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India	54
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials	54
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, p	54
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study	54
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study	53
Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses	53
The role of schools and school-aged children in SARS-CoV-2 transmission	53
Decarceration and community re-entry in the COVID-19 era	52
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents	52
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5	52
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	51
Dental procedure aerosols and COVID-19	51
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach	51
A need for open public data standards and sharing in light of COVID-19	51
Arthritogenic alphaviruses: epidemiological and clinical perspective on emerging arboviruses	51
Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial	51
Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: a multisite prospective longitudinal cohort study	51
SARS-CoV-2 incidence and vaccine escape	51
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	50
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study	50
Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study	50
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial	49